Alyeska Investment Group’s Windtree Therapeutics WINT Stock Holding History

Alyeska Investment Group’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-152	Closed	-$98.2K	–	634
2023 Q4	$98.2K	Hold	152	–	–	﹤0.01%	490
2023 Q3	$130K	Buy	+152	New	+$168K	﹤0.01%	467

Other funds holding WINT

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Alyeska Investment Group's WINT Position: Q1 2024 in Review

Alyeska Investment Group sold out of Windtree Therapeutics (WINT) in Q1 2024, closing a stake of 152 shares — an estimated $98.2K sold.

Alyeska Investment Group first reported a position in WINT in Q3 2023 and held it in 2 quarters. The position peaked at $130K in Q3 2023. 4 funds tracked by Wall St. Rank hold WINT as of Q1 2024.

Alyeska Investment Group reported no remaining Windtree Therapeutics position as of Q1 2024 after selling out during the quarter.
Alyeska Investment Group sold 152 Windtree Therapeutics shares in Q1 2024, an estimated $98.2K.
Alyeska Investment Group first reported a position in Windtree Therapeutics in Q3 2023 and held it in 2 quarters.
Alyeska Investment Group's Windtree Therapeutics position peaked at $130K in Q3 2023.
4 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2024.

Based on Alyeska Investment Group's 13F filing for Q1 2024, filed 15 May 2024.